Capacity of tumor necrosis factor to augment lymphocyte-mediated tumor cell lysis of malignant mesothelioma
Journal Article
·
· Clinical Immunology and Immunopathology; (USA)
- Univ. of Western Australia, Nedlands (Australia)
Recombinant human tumor necrosis factor (rHuTNF) was evaluated both for direct anti-tumor action against human malignant mesothelioma and for its capacity to augment the generation and lytic phases of lymphocyte-mediated cytotoxicity against this tumor. rHuTNF was directly toxic by MTT assay to one of two mesothelioma cell lines evaluated, but had no effect on susceptibility to subsequent lymphocyte-mediated lysis of either line. TNF alone was incapable of generating anti-mesothelioma lymphokine-activated killer cell (LAK) activity. Furthermore, it did not augment the degree or LAK activity produced by submaximal interleukin-2 (IL-2) concentrations nor did it augment lysis of mesothelioma cells by natural killer (NK) or LAK effector cells during the 4-hr 51chromium release cytolytic reaction. The studies also suggest that mesothelioma targets are less responsive to TNF plus submaximal IL-2 concentrations than the standard LAK sensitive target Daudi, raising the possibility that intermediate LAK sensitive tumors such as mesothelioma may require separate and specific evaluation in immunomodulation studies. This in vitro study indicates that use of low-dose rHuTNF and IL-2 is unlikely to be an effective substitute for high-dose IL-2 in generation and maintenance of LAK activity in adoptive immunotherapy for mesothelioma.
- OSTI ID:
- 6271989
- Journal Information:
- Clinical Immunology and Immunopathology; (USA), Journal Name: Clinical Immunology and Immunopathology; (USA) Vol. 58:1; ISSN CLIIA; ISSN 0090-1229
- Country of Publication:
- United States
- Language:
- English
Similar Records
Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes
Indomethacin augments lymphokine-activated killer cell generation by patients with malignant mesothelioma
Anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: direct correlation between reduction of established metastases and cytolytic activity of lymphokine-activated killer cells
Journal Article
·
Tue Jun 01 00:00:00 EDT 1982
· J. Exp. Med.; (United States)
·
OSTI ID:6783095
Indomethacin augments lymphokine-activated killer cell generation by patients with malignant mesothelioma
Journal Article
·
Sun Oct 01 00:00:00 EDT 1989
· Clinical Immunology and Immunopathology; (USA)
·
OSTI ID:5346589
Anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: direct correlation between reduction of established metastases and cytolytic activity of lymphokine-activated killer cells
Journal Article
·
Thu May 15 00:00:00 EDT 1986
· J. Immunol.; (United States)
·
OSTI ID:5650996
Related Subjects
550901* -- Pathology-- Tracer Techniques
59 BASIC BIOLOGICAL SCIENCES
ANIMAL CELLS
ANIMALS
BETA DECAY RADIOISOTOPES
BIOLOGICAL FUNCTIONS
BIOLOGICAL MATERIALS
BLOOD
BLOOD CELLS
BODY FLUIDS
CELL PROLIFERATION
CHROMIUM 51
CHROMIUM ISOTOPES
CONNECTIVE TISSUE CELLS
DISEASES
ELECTRON CAPTURE RADIOISOTOPES
EVEN-ODD NUCLEI
FUNCTIONS
GROWTH FACTORS
INTERMEDIATE MASS NUCLEI
ISOTOPE APPLICATIONS
ISOTOPES
LEUKOCYTES
LYMPHOCYTES
LYMPHOKINES
LYSIS
MAMMALS
MAN
MATERIALS
MITOGENS
NEOPLASMS
NUCLEI
ORGANIC COMPOUNDS
PRIMATES
PROTEINS
RADIOISOTOPES
SOMATIC CELLS
TRACER TECHNIQUES
TUMOR CELLS
VERTEBRATES
59 BASIC BIOLOGICAL SCIENCES
ANIMAL CELLS
ANIMALS
BETA DECAY RADIOISOTOPES
BIOLOGICAL FUNCTIONS
BIOLOGICAL MATERIALS
BLOOD
BLOOD CELLS
BODY FLUIDS
CELL PROLIFERATION
CHROMIUM 51
CHROMIUM ISOTOPES
CONNECTIVE TISSUE CELLS
DISEASES
ELECTRON CAPTURE RADIOISOTOPES
EVEN-ODD NUCLEI
FUNCTIONS
GROWTH FACTORS
INTERMEDIATE MASS NUCLEI
ISOTOPE APPLICATIONS
ISOTOPES
LEUKOCYTES
LYMPHOCYTES
LYMPHOKINES
LYSIS
MAMMALS
MAN
MATERIALS
MITOGENS
NEOPLASMS
NUCLEI
ORGANIC COMPOUNDS
PRIMATES
PROTEINS
RADIOISOTOPES
SOMATIC CELLS
TRACER TECHNIQUES
TUMOR CELLS
VERTEBRATES